This article is more than 5 years old. Information may no longer be current.

Conjunctival neoplasia regress with mitomycin treatment, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Mitomycin C treatment was effective in treating corneal conjunctival intraepithelial neoplasia in a clinical study. An optimal treatment regimen is still to be established, the study authors noted.

M. Daniell and colleagues used mitomycin-C to treat 20 cases of corneal conjunctival intraepithelial neoplasia in which the disease recurred (17) or patients refused surgery (3). All patients were treated with topical mitomycin, in either 0.02% or 0.04% solution. All patients applied mitomycin eye drops four times daily for 1 week, followed by 1 week off, then another week of treatment.

Clinical resolution of lesions occurred in 18 of the 20 cases. Epithelial toxicity occurred in 50% of the eyes and lid toxicity in two eyes. No long-term complications were associated with the drug use.

The study is published in the Journal of Community Eye Health.